Close Menu

Bristol-Myers Squibb announced plans to lay off 4,300 employees and close more than half of its manufacturing plants in a cost-saving, "right-sizing" move. Followed by Pfizer and Merck, it's the third big pharma company to take action against the looming generics competition. In the Pipeline's Derek Lowe thinks it's not a bad thing, as long as R&D is left alone to do what they do best -- discover new drug compounds.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A South African university has told the Wellcome Sanger Institute to return DNA samples it has from indigenous African communities, The Times reports.

The University of California, Berkeley's Rasmus Nielsen and Xinzhu Wei have retracted their CCR5 gene paper due to a technical artifact.

 

University of Virginia researchers are exploring a genetic risk test to gauge type 1 diabetes risk, NPR reports.

In PNAS this week: researchers compare two high-grade neuroendocrine lung cancers, height among ancient Europeans, and more.